International Journal of Drug Delivery Technology
Volume 15, Issue 2

Formulation Optimization of Hydrogel-Based Contact Lenses for Dual-Drug Delivery in Glaucoma Treatment

Vangol Varshitha, Umadevi S*

 School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai- 600 117, Tamil Nadu, India 

Received: 21st Mar, 2025; Revised: 14th Apr, 2025; Accepted: 24th May, 2025; Available Online: 25th Jun, 2025 

ABSTRACT

Glaucoma is a chronic ophthalmic disorder that necessitates long-term therapeutic management to prevent progressive vision loss. Conventional eye drop formulations suffer from rapid precorneal drug elimination, leading to poor bioavailability and frequent dosing requirements. In this study, hydrogel-based contact lenses were developed and optimized for the sustained dual-drug delivery of Timolol Maleate and Brimonidine Tartrate, two first-line antiglaucoma agents. The formulation was optimized using Box-Behnken Design (BBD), where the effects of HEMA concentration (85-95%), EGDMA crosslinker concentration (0.5-1.5%), drug loading (2-6 mg/mL), and water content (30-50%) were evaluated on key parameters such as swelling ratio, tensile strength, optical transparency, drug release kinetics, and drug retention. The optimized formulation exhibited a swelling ratio of 169.1%, tensile strength of 1.2 MPa, and over 95% transparency, ensuring structural integrity and visual clarity. FTIR and DSC confirmed the compatibility of the drug-polymer system, with no significant chemical interactions observed. In vitro swelling studies demonstrated that higher HEMA content promoted hydration, while increased EGDMA crosslinking reduced water uptake, thereby modulating drug diffusion. The cumulative in vitro drug release study revealed a sustained release profile, with Timolol Maleate and Brimonidine Tartrate achieving 96.25% and 97.42% release, respectively, within 24 hours. Drug release followed First-order, Higuchi, and Korsmeyer-Peppas models, indicating diffusion-controlled, non-Fickian kinetics. This suggests hydrogel-based contact lenses provide sustained drug delivery, reducing dosing frequency and improving compliance in glaucoma therapy compared to conventional eye drops.

Keywords: Hydrogel contact lenses, sustained drug release, glaucoma therapy, Timolol Maleate, Brimonidine Tartrate, Box-Behnken Design, drug delivery optimization

How to cite this article: Vangol Varshitha, Umadevi S. Formulation Optimization of Hydrogel-Based Contact Lenses for Dual-Drug Delivery in Glaucoma Treatment. International Journal of Drug Delivery Technology. 2025;15(2): 763-69. doi:10.25258/ijddt.15.2.50

REFERENCES

  1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-7.
  2. Quellec G, Charrière K, Boudi Y, Cochener B, Lamard M. Deep image mining for diabetic retinopathy screening. Med Image Anal. 2017;39:178-193.
  3. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901-11.
  4. Januleviciene I, Siaudvytyte L, Barsauskaite R. Ophthalmic drug delivery in glaucoma-a review. Pharmaceutics. 2012 Mar 21;4(1):243-51. Doi: 10.3390/pharmaceutics4010243
  5. Kompella UB, Hartman RR, Patil MA. Extraocular, periocular, and intraocular routes for sustained drug delivery for glaucoma. Prog Retin Eye Res. 2021; 82:100901.
  6. Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010 ;12(3):348-60.
  7. Kholdebarin R, Campbell RJ, Jin YP, Buys YM. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol. 2008;43(4):454-61.
  8. Gupta VS, Sethi H, Naik M. Strategies to Improve Glaucoma Compliance Based on Cross-Sectional Response-Based Data in a Tertiary Healthcare Center: The Glauco-Jung Study. J Curr Glaucoma Pract. 2015;9(2):38-46.
  9. Newman-Casey PA, Robin AL, Blachley T, Farris K, Heisler M, Resnicow K, Lee PP. The Most Common Barriers to Glaucoma Medication Adherence: A Cross-Sectional Survey. Ophthalmology. 2015;122(7):1308-16.
  10. Fingeret M, Dickerson JE Jr. The Role of Minimally Invasive Glaucoma Surgery Devices in the Management of Glaucoma. Optom Vis Sci. 2018;95(2):155-162.
  11. Jung HJ, Chauhan A. Temperature sensitive contact lenses for triggered ophthalmic drug delivery. Biomaterials. 2012;33(7):2289-300.
  12. Ioniță M, Vlăsceanu GM, Toader AG, Manole M. Advances in Therapeutic Contact Lenses for the Management of Different Ocular Conditions. J Pers Med. 2023 ;13(11):1571.
  13. Li, C. C., & Chauhan, A. (2006). Modeling ophthalmic drug delivery by soaked contact lenses. Industrial & Engineering Chemistry Research, 2006;45(10):3718-3734.
  14. Rykowska I, Nowak I, Nowak R. Soft Contact Lenses as Drug Delivery Systems: A Review. Molecules. 2021 Sep 14;26(18):5577.
  15. Nguyen QH. Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus. Patient Prefer Adherence. 2014 Jun 12;8:853-64.
  16. Ciolino JB, Stefanescu CF, Ross AE, Salvador-Culla B, Cortez P, Ford EM, Wymbs KA, Sprague SL, Mascoop DR, Rudina SS, Trauger SA, Cade F, Kohane DS. In vivo performance of a drug-eluting contact lens to treat glaucoma for a month. Biomaterials. 2014 Jan;35(1):432-9. .
  17. Carvalho IM, Marques CS, Oliveira RS, Coelho PB, Costa PC, Ferreira DC. Sustained drug release by contact lenses for glaucoma treatment-a review. J Control Release. 2015 28;202:76-82.
  18. Jain PS, Chaudhari AJ, Patel SA, Patel ZN, Patel DT. Development and validation of the UV-spectrophotometric method for determination of terbinafine hydrochloride in bulk and in formulation. Pharm Methods. 2011;2(3):198-202.
  19. Pramod, K., Suneesh, C.V., Shanavas, S. et al. Unveiling the compatibility of eugenol with formulation excipients by systematic drug-excipient compatibility studies. J Anal Sci Technol. 2015;6:34.